Cowen Research Themes 2021 has been published. Click here to learn about the year's key investment themes. >

$144 Million

NGM Biopharmaceuticals, Inc.

Follow-on Offering

Bookrunner, January 2021

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver and metabolic diseases, retinal diseases and cancer. The Company’s lead product candidate, aldafermin (formerly known as NGM282), is an engineered version of the human hormone FGF19 that is administered through a once-daily subcutaneous injection.

More Like This

Jan 2021
$144 Million
DermTech logo

Follow-on Offering

Lead Left Bookrunner

View Details
Jan 2021
$225 Million

Follow-on Offering

Bookrunner

View Details
Dec 2020
$145 Million

Follow-on Offering

Lead Left Bookrunner

View Details